Harbor Investment Advisory’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-26
Closed -$5.19K 1256
2025
Q4
$5.19K Sell
26
-276
-91% -$50.1K ﹤0.01% 1047
2025
Q3
$47.3K Sell
302
-253
-46% -$40.2K ﹤0.01% 654
2025
Q2
$84.2K Buy
555
+164
+42% +$21.9K 0.01% 530
2025
Q1
$58.9K Sell
391
-195
-33% -$32.7K 0.01% 571
2024
Q4
$108K Buy
586
+15
+3% +$2.89K 0.01% 442
2024
Q3
$112K Sell
571
-351
-38% -$72.9K 0.01% 437
2024
Q2
$190K Buy
922
+328
+55% +$74.3K 0.02% 340
2024
Q1
$161K Sell
594
-350
-37% -$83.6K 0.02% 373
2023
Q4
$223K Buy
944
+80
+9% +$15.7K 0.03% 309
2023
Q3
$169K Buy
864
+530
+159% +$109K 0.02% 328
2023
Q2
$70.2K Buy
334
+234
+234% +$46.6K 0.01% 607
2023
Q1
$20.2K Hold
100
﹤0.01% 911
2022
Q4
$21.8K Hold
100
﹤0.01% 887
2022
Q3
$20K Hold
100
﹤0.01% 908
2022
Q2
$21K Hold
100
﹤0.01% 895
2022
Q1
$28K Hold
100
﹤0.01% 875
2021
Q4
$38K Hold
100
﹤0.01% 815
2021
Q3
$41K Hold
100
0.01% 785
2021
Q2
$37K Hold
100
0.01% 779
2021
Q1
$29K Buy
+100
New +$27.8K ﹤0.01% 803

Other funds holding CRL

Harbor Investment Advisory's CRL Position: Q1 2026 in Review

Harbor Investment Advisory sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 26 shares — an estimated $5.19K sold.

Harbor Investment Advisory first reported a position in CRL in Q1 2021 and held it in 20 quarters. The position peaked at $223K in Q4 2023. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Harbor Investment Advisory reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Harbor Investment Advisory sold 26 Charles River Laboratories shares in Q1 2026, an estimated $5.19K.
  • Harbor Investment Advisory first reported a position in Charles River Laboratories in Q1 2021 and held it in 20 quarters.
  • Harbor Investment Advisory's Charles River Laboratories position peaked at $223K in Q4 2023.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Harbor Investment Advisory's 13F filing for Q1 2026, filed 23 Apr 2026.